Home > Drugs A-Z > Klor-Con

Klor-Con (Aphena Pharma Solutions - Tennessee, LLC)

Available Formats

Dosage Form Package Information Links
TABLET, FILM COATED, EXTENDED RELEASE 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (67544-154-60) Label Information
TABLET, FILM COATED, EXTENDED RELEASE 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (67544-154-53) Label Information
TABLET, FILM COATED, EXTENDED RELEASE 360 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (67544-154-94) Label Information
TABLET, FILM COATED, EXTENDED RELEASE 180 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (67544-154-80) Label Information

Complete Klor-Con Information

  • DESCRIPTION

    Klor-Con® Extended-release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a wax matrix tablet. This formulation is intended to provide an extended-release of potassium from the matrix to minimize the likelihood of producing high, localized concentrations of potassium within the gastrointestinal tract.

    Klor-Con® Extended-release Tablets are an electrolyte replenisher. The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a white, granular powder or colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol.

    Inactive Ingredients: Hydrogenated vegetable oil, magnesium stearate, polyethylene glycol, polyvinyl alcohol, silicon dioxide, talc and titanium dioxide. Yellow tablets also contain D&C Yellow No. 10 aluminum lake and FD&C Yellow No. 6 aluminum lake. Blue tablets also contain FD&C Blue No. 1 aluminum lake and FD&C Blue No. 2 aluminum lake.


  • CLINICAL PHARMACOLOGY

    The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function.

    The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.

    Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.

    Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops slowly as a consequence of prolonged therapy with oral diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis, severe diarrhea, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine.

    If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.

    In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate or potassium gluconate.

    The potassium chloride in Klor-Con® Extended-release Tablets is completely absorbed before it leaves the small intestine. The wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. When the bioavailability of the potassium ion from the Klor-Con® Extended-release Tablets is compared to that of a true solution the extent of absorption is similar.

    The extended-release properties of Klor-Con® Extended-release Tablets are demonstrated by the finding that a significant increase in time is required for renal excretion of the first 50% of the Klor-Con® Extended-release Tablets dose as compared to the solution.

    Increased urinary potassium excretion is first observed 1 hour after administration of Klor-Con® Extended-release Tablets, reaches a peak at 4 hours, and extends up to 8 hours. Mean daily steady-state plasma levels of potassium following daily administration of Klor-Con® Extended-release Tablets cannot be distinguished from those following administration of potassium chloride solution or from control plasma levels of potassium ion.


  • INDICATIONS AND USAGE

    BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH EXTENDED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.

    1. For the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.
    2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

    The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.


  • CONTRAINDICATIONS

    Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride) (see OVERDOSAGE).

    Extended-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to an enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation.

    All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis) or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.


  • WARNINGS

    Hyperkalemia (see OVERDOSAGE): In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic.

    The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.

    Interaction with Potassium-sparing Diuretics: Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene or amiloride), since the simultaneous administration of these agents can produce severe hyperkalemia.

    Interaction with Angiotensin Converting Enzyme Inhibitors: Angiotensin converting enzyme (ACE) inhibitors (e.g., captopril, enalapril) will produce some potassium retention by inhibiting aldosterone production. Potassium supplements should be given to patients receiving ACE inhibitors only with close monitoring.

    Gastrointestinal Lesions: Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric-coated preparations of potassium chloride are associated with an increased frequency of small bowel lesions (40-50 per 100,000 patient years) compared to extended-release wax matrix formulations (less than one per 100,000 patient years). Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Klor-Con® Extended-release Tablets are wax matrix tablets formulated to provide an extended rate of release of potassium chloride and thus to minimize the possibility of high local concentration of potassium near the gastrointestinal wall.

    Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after one week of solid oral potassium chloride therapy. The ability of this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix extended-release formulation under conditions which did not resemble usual or recommended clinical practice (i.e., 96 mEq per day in divided doses of potassium chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying). The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of bleeding (hemoccult testing). The relevance of these findings to the usual conditions (i.e., non-fasting, no anticholinergic agent, smaller doses) under which extended-release potassium chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations. Klor-Con® Extended-release Tablets should be discontinued immediately and the possibility of ulceration, obstruction or perforation considered if severe vomiting, abdominal pain, distention or gastrointestinal bleeding occurs.

    Metabolic Acidosis: Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, potassium acetate or potassium gluconate.


  • PRECAUTIONS

    General: The diagnosis of potassium depletion is ordinarily made by demonstrating hypokalemia in a patient with a clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should be aware that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium while acute acidosis per se can increase the serum potassium concentration into the normal range even in the presence of a reduced total body potassium. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease or acidosis requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, the electrocardiogram and the clinical status of the patient.

    Information for Patients: Physicians should consider reminding the patient of the following:

     
    • To take each dose with meals and with a full glass of water or other liquid.
     
    • To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations.
     
    • To check with the physician if there is trouble swallowing the tablets or if the tablets seem to stick in the throat.
     
    • To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.
     
    • To take each dose without crushing, chewing or sucking the tablets.

    Laboratory Tests: When blood is drawn for analysis of plasma potassium it is important to recognize that artifactual elevations can occur after improper venipuncture technique or as a result of in vitro hemolysis of the sample.

    Drug Interactions: Potassium-sparing diuretic, angiotensin converting enzyme inhibitors (see WARNINGS).

    Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.

    Pregnancy: Pregnancy Category C. Animal reproduction studies have not been conducted with Klor-Con® Extended-release Tablets. It is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity.

    Nursing Mothers: The normal potassium ion content of human milk is about 13 mEq per liter. It is not known if Klor-Con® Extended-release Tablets have an effect on this content. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.

    Pediatric Use: Safety and effectiveness in the pediatric population have not been established.

    Geriatric Use: Clinical studies of Klor-Con® Extended-release Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

    This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.


  • ADVERSE REACTIONS

    One of the most severe adverse effects is hyperkalemia (see CONTRAINDICATIONS, WARNINGS and OVERDOSAGE). There also have been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration and perforation (see CONTRAINDICATIONS and WARNINGS).

    The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by taking the dose with meals or reducing the amount taken at one time.

    Skin rash has been reported rarely.


  • OVERDOSAGE

    The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result (see CONTRAINDICATIONS and WARNINGS). It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).

    Treatment measures for hyperkalemia include the following:

    1. Elimination of foods and medications containing potassium and of any agents with potassium-sparing properties.
    2. Intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10-20 units of crystalline insulin per 1,000 mL.
    3. Correction of acidosis, if present, with intravenous sodium bicarbonate.
    4. Use of exchange resins, hemodialysis or peritoneal dialysis.

    In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.

    The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.


  • DOSAGE AND ADMINISTRATION

    The usual dietary potassium intake by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 mEq or more of potassium from the total body store.

    Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40-100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose.

    Each Klor-Con® Extended-release Tablet provides 8 mEq or 10 mEq of potassium chloride.

    Klor-Con® Extended-release Tablets should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation (see WARNINGS).

    NOTE: Klor-Con® Extended-release Tablets must be swallowed whole and never crushed, chewed, or sucked.


  • HOW SUPPLIED

    Repackaged by Aphena Pharma Solutions - TN.
    See Repackaging Information for available configurations.

    Aphena Pharma Solutions - TN

    Film-coated Klor-Con® 8 (light blue, debossed with "KC 8"), Klor-Con® 10 (yellow, debossed with "KC 10"), round tablets containing:

     
    • 600 mg potassium chloride (equivalent to 8 mEq) in bottles of 100 (NDC 0245-0040-11), bottles of 500 (NDC 0245-0040-15), unit dose packages of 100 (NDC 0245-0040-01), bulk packs of 5,000 for repack only (NDC 0245-0040-55), and bulk packs of 10,000 for repack only (NDC 0245-0040-00);
     
    • 750 mg potassium chloride (equivalent to 10 mEq) in bottles of 100 (NDC 0245-0041-11), bottles of 500 (NDC 0245-0041-15), unit dose packages of 100 (NDC 0245-0041-01), bulk packs of 5,000 for repack only (NDC 0245-0041-55), and bulk packs of 10,000 for repack only (NDC 0245-0041-00).

    Store at controlled room temperature, 15-30°C (59-86°F). Protect from light and moisture. Dispense in a tight container with child-resistant closure.


  • SPL UNCLASSIFIED SECTION

    Manufactured by
    UPSHER-SMITH LABORATORIES, INC.
    Minneapolis, MN 55447

    Revised 1008


  • Repackaging Information

    Please reference the How Supplied section listed above for a description of individual tablets or capsules. This drug product has been received by Aphena Pharma - TN in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations. The package configurations available from Aphena are listed below:

    Count 8 mEq K 10 mEq K
    30 - 67544-237-30
    60 67544-154-53 67544-237-53
    90 67544-154-60 67544-237-60
    100 - 67544-237-65
    120 - 67544-237-70
    180 67544-154-80 67544-237-80
    200 - 67544-237-85
    270 - 67544-237-92
    360 67544-154-80 67544-237-94

    Store between 20°-25°C (68°-77°F). See USP Controlled Room Temperature. Dispense in a tight light-resistant container as defined by USP. Keep this and all drugs out of the reach of children.

    Repackaged by:
    Aphena Pharma Solutions - TN
    Cookeville, TN 38506

    201305146AW


  • PRINCIPAL DISPLAY PANEL - 8 mEq K

    NDC 67544-154 - Potassium Chloride (Klor-Con® 8) 8 mEq K - Rx Only
    Bottle Label 8 mEq K


  • PRINCIPAL DISPLAY PANEL - 10 meq K

    NDC 67544-237 - Potassium Chloride (Klor-Con® 10) 10 mEq K - Rx Only
    Bottle Label 10 mEq K


  • INGREDIENTS AND APPEARANCE
    KLOR-CON 
    potassium chloride tablet, film coated, extended release
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67544-154(NDC:0245-0040)
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Potassium Chloride (UNII: 660YQ98I10) (Potassium Cation - UNII:295O53K152) Potassium Chloride 600 mg
    Inactive Ingredients
    Ingredient Name Strength
    hydrogenated cottonseed oil (UNII: Z82Y2C65EA)  
    magnesium stearate (UNII: 70097M6I30)  
    polyethylene glycols (UNII: 3WJQ0SDW1A)  
    polyvinyl alcohol (UNII: 532B59J990)  
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    talc (UNII: 7SEV7J4R1U)  
    titanium dioxide (UNII: 15FIX9V2JP)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    Product Characteristics
    Color BLUE (light blue) Score no score
    Shape ROUND Size 11mm
    Flavor Imprint Code KC;8
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:67544-154-53 60 in 1 BOTTLE, PLASTIC
    2 NDC:67544-154-60 90 in 1 BOTTLE, PLASTIC
    3 NDC:67544-154-80 180 in 1 BOTTLE, PLASTIC
    4 NDC:67544-154-94 360 in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA019123 04/17/1986
    KLOR-CON 
    potassium chloride tablet, film coated, extended release
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:67544-237(NDC:0245-0041)
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Potassium Chloride (UNII: 660YQ98I10) (Potassium Cation - UNII:295O53K152) Potassium Chloride 750 mg
    Inactive Ingredients
    Ingredient Name Strength
    hydrogenated cottonseed oil (UNII: Z82Y2C65EA)  
    magnesium stearate (UNII: 70097M6I30)  
    polyethylene glycols (UNII: 3WJQ0SDW1A)  
    polyvinyl alcohol (UNII: 532B59J990)  
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    talc (UNII: 7SEV7J4R1U)  
    titanium dioxide (UNII: 15FIX9V2JP)  
    d&c yellow no. 10 (UNII: 35SW5USQ3G)  
    aluminum oxide (UNII: LMI26O6933)  
    fd&c yellow no. 6 (UNII: H77VEI93A8)  
    Product Characteristics
    Color YELLOW Score no score
    Shape ROUND Size 13mm
    Flavor Imprint Code KC;10
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:67544-237-30 30 in 1 BOTTLE, PLASTIC
    2 NDC:67544-237-53 60 in 1 BOTTLE, PLASTIC
    3 NDC:67544-237-60 90 in 1 BOTTLE, PLASTIC
    4 NDC:67544-237-65 100 in 1 BOTTLE, PLASTIC
    5 NDC:67544-237-70 120 in 1 BOTTLE, PLASTIC
    6 NDC:67544-237-80 180 in 1 BOTTLE, PLASTIC
    7 NDC:67544-237-85 200 in 1 BOTTLE, PLASTIC
    8 NDC:67544-237-92 270 in 1 BOTTLE, PLASTIC
    9 NDC:67544-237-94 360 in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA019123 04/17/1986
    Labeler - Aphena Pharma Solutions - Tennessee, LLC (128385585)
    Establishment
    Name Address ID/FEI Business Operations
    Aphena Pharma Solutions - Tennessee, LLC 128385585 Repack(67544-154, 67544-237)